Hydroxyurea in Young Children With Sickle Cell Anemia

• Status: Completed
• Trial end date: 2007-02-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to asses prospectively the safety and efficacy of hydroxyurea therapy in children with Sickle cell Anemia between ages 18 months and 5 years, with special emphasis on the ability of hydroxyurea to prevent or reverse chronic organ damage.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Duke University
• Treatments: Hydroxyurea

Criteria

Inclusion Criteria:

• Clinical diagnosis of Sickle Cell Anemia (Hb SS or Hb S beta zero-thalassemia)